Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia [PDF]
, 2017 C. J. Owen +5 more
core +1 more source
Targeting Tumor Stroma: Current Challenges and Future Directions
MedComm, Volume 7, Issue 5, May 2026.Figure 1. Mechanism of ECM reprogramming. Cancer‐associated fibroblasts (CAFs), cancer‐associated macrophages (CAMs), and other mesenchymal cells alter the ECM composition and increase its stiffness by depositing matrix components such as collagen and hyaluronic acid, and secreting cross‐linking agents like lysyl oxidase homolog 2 (LOXL2).
Siwei Wang +7 more
wiley +1 more source
Pharmacoepidemiology and Drug Safety, Volume 35, Issue 5, May 2026.ABSTRACT Purpose To report the experience of the Italian Working Group on DDD (Ita‐DDD‐wg) in assigning DDDs to a list of antineoplastic agents. Methods Active substances from the ATC L01 group with no assigned DDD and reimbursed at least once during 2021 by the Italian Healthcare Service were identified.
Angela Boccia +21 more
wiley +1 more source
Mechanistic overview and suggested strategies to overcome BCL-2 inhibitor resistance in <i>TP53-</i>mutated acute myeloid leukemia. [PDF]
Front Cell Dev BiolIqbal U, Shallis RM.
europepmc +1 more source
Hypomethylating agents plus venetoclax in younger acute myeloid leukemia: Meta-analysis of a shifting treatment paradigm. [PDF]
CancerPerrone S +3 more
europepmc +1 more source
Effects and molecular mechanism of inhibiting p53 signaling pathway by NSUN4 on the resistance to BCL-2 inhibitor for diffuse large B-cell lymphoma. [PDF]
Clin Exp MedShi Y +9 more
europepmc +1 more source
The combination therapy with venetoclax in therapeutic strategy of acute lymphoblastic leukemia. [PDF]
Discov OncolShamahmood MN +3 more
europepmc +1 more source
Emerging therapeutics for the treatment of light chain and transthyretin amyloidosis [PDF]
, 2019 Lenihan, Daniel J +2 more
core +1 more source